Pyridazinone kinase inhibitors

Details Pyridazinone kinase inhibitors Pyridazinone kinase inhibitors

2011-06-28

2011-06-28

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S238000

Reexamination Certificate

active

07968546

ABSTRACT:
Disclosed are compounds of Formula Iwherein X isand R2, R1, A, B, D, E, R9are as defined herein useful for treating cancers.

REFERENCES:
patent: 4353905 (1982-10-01), Sircar et al.
patent: 4734415 (1988-03-01), Sircar et al.
patent: 5607944 (1997-03-01), Linz et al.
patent: 2009/0035267 (2009-02-01), Moore et al.
patent: 0 075 436 (1983-03-01), None
patent: 0 639 575 (1995-02-01), None
patent: 9216883 (1997-08-01), None
patent: 09216883 (1997-08-01), None
patent: WO 01/29025 (2001-04-01), None
patent: WO 02/22605 (2002-03-01), None
patent: WO 02/092593 (2002-11-01), None
patent: WO03/028721 (2003-04-01), None
patent: WO 03/059891 (2003-07-01), None
patent: WO 2004/046130 (2004-06-01), None
patent: WO 2005/085230 (2005-09-01), None
patent: WO 2005/085231 (2005-09-01), None
Griesser Chapter 8, The Importance of Solvates (pp. 211-230), in the text, Polymorphism: In the Pharmaceutical Industry, Hilfiker, 2006.
Sayed, et al., Molecules (2003), 8(3), 322-332.
Griesser, Polymorphism: In the Pharmaceutical Industry, Chapter 8, The Importance of Solvates, 2006, pp. 126-127.
Huwe et al, Small Molecules As Inhibitors of Cyclin-Dependent Kinases, Ange. Chem. Int. Ed. 2003, 42, pp. 2122-2138.
Lee et al, Regulators of G1 Cyclin-Dependent Kinases and Cancers, Cancer and Metastasis Reviews 22: 435-449, 2003.

Affiliated with

Also associated with

Rating

Pyridazinone kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridazinone kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridazinone kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2651468